蓝帆医疗: 关于向下修正蓝帆转债转股价格的公告

Core Viewpoint - The company has decided to lower the conversion price of its convertible bonds, "蓝帆转债," to 12.00 CNY per share, effective from July 8, 2025, due to stock price performance and future development considerations [3][6]. Group 1: Convertible Bond Issuance and Adjustment - The total amount of the convertible bonds issued by the company was 314.404 million CNY, approved by the China Securities Regulatory Commission [1]. - The initial conversion price was set at 17.79 CNY per share, which was later adjusted to 18.64 CNY per share after the company repurchased and canceled 48,148,336 shares as part of a performance compensation plan [2][3]. - The conversion price was further adjusted to 12.50 CNY per share on May 21, 2024, following the approval of the shareholders [3][4]. Group 2: Conditions for Price Adjustment - The adjustment of the conversion price is triggered when the closing price of the company's stock is below the current conversion price for at least 15 out of 30 consecutive trading days [4][5]. - The new conversion price must not be lower than the higher of the average trading price over the 20 days prior to the shareholders' meeting and the last trading day's price, as well as not lower than the latest audited net asset value per share [4][5]. Group 3: Recent Developments - The average trading price of the company's stock was 5.63 CNY per share over the 20 days prior to the second extraordinary shareholders' meeting in 2025, and 5.94 CNY on the last trading day before the meeting [5][6]. - The latest audited net asset value per share was reported at 8.13 CNY, which sets a minimum threshold for the conversion price adjustment [5].